BR112019016024A2 - Métodos para o tratamento de câncer utilizando inibidores de hsp90 - Google Patents

Métodos para o tratamento de câncer utilizando inibidores de hsp90 Download PDF

Info

Publication number
BR112019016024A2
BR112019016024A2 BR112019016024-8A BR112019016024A BR112019016024A2 BR 112019016024 A2 BR112019016024 A2 BR 112019016024A2 BR 112019016024 A BR112019016024 A BR 112019016024A BR 112019016024 A2 BR112019016024 A2 BR 112019016024A2
Authority
BR
Brazil
Prior art keywords
cancer
inhibitor
bcl
hsp90
hsp90 inhibitor
Prior art date
Application number
BR112019016024-8A
Other languages
English (en)
Portuguese (pt)
Inventor
BEEHARRY Neil
HERNANDEZ Marylens
LANDRETTE Sean
Xu Tian
M. Rothberg Jonathan
Lichenstein Henri
Original Assignee
AI Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AI Therapeutics, Inc. filed Critical AI Therapeutics, Inc.
Publication of BR112019016024A2 publication Critical patent/BR112019016024A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112019016024-8A 2017-02-03 2018-02-01 Métodos para o tratamento de câncer utilizando inibidores de hsp90 BR112019016024A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762454113P 2017-02-03 2017-02-03
US62/454,113 2017-02-03
US201762563991P 2017-09-27 2017-09-27
US62/563,991 2017-09-27
US201762587886P 2017-11-17 2017-11-17
US62/587,886 2017-11-17
PCT/US2018/016361 WO2018144680A1 (en) 2017-02-03 2018-02-01 Methods for treating cancer using hsp90 inhibitors

Publications (1)

Publication Number Publication Date
BR112019016024A2 true BR112019016024A2 (pt) 2020-03-31

Family

ID=63038389

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019016024-8A BR112019016024A2 (pt) 2017-02-03 2018-02-01 Métodos para o tratamento de câncer utilizando inibidores de hsp90

Country Status (13)

Country Link
US (2) US10799508B2 (cg-RX-API-DMAC7.html)
EP (1) EP3576794A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020505433A (cg-RX-API-DMAC7.html)
KR (1) KR20190110128A (cg-RX-API-DMAC7.html)
CN (1) CN110536702A (cg-RX-API-DMAC7.html)
AU (1) AU2018215336A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019016024A2 (cg-RX-API-DMAC7.html)
CA (1) CA3052594A1 (cg-RX-API-DMAC7.html)
IL (1) IL268430A (cg-RX-API-DMAC7.html)
MX (1) MX2019009227A (cg-RX-API-DMAC7.html)
RU (1) RU2019127350A (cg-RX-API-DMAC7.html)
TW (1) TW201840337A (cg-RX-API-DMAC7.html)
WO (1) WO2018144680A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3052594A1 (en) 2017-02-03 2018-08-09 AI Therapeutics, Inc. Methods for treating cancer using hsp90 inhibitors
CA3076915A1 (en) * 2017-09-27 2019-04-04 AI Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors
EP3876941A1 (en) * 2018-11-08 2021-09-15 GlaxoSmithKline Intellectual Property Development Limited Combination of prmt5 inhibitors and bcl-2 inhibitors
WO2020160192A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160193A2 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2022540317A (ja) * 2019-06-25 2022-09-15 ターベダ セラピューティクス インコーポレイテッド Hsp90結合コンジュゲートおよびその併用療法
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4054585A1 (en) 2019-11-05 2022-09-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4101468A4 (en) * 2020-02-05 2024-02-28 Carna Biosciences, Inc. Anticancer agent composition
KR102683903B1 (ko) * 2020-09-16 2024-07-12 한국원자력의학원 아리피프라졸을 유효성분으로 함유하는 bcl2 저해제의 항암 효과 증진용 조성물
WO2022061174A1 (en) * 2020-09-17 2022-03-24 Albert Einstein College Of Medicine Combination therapy using bax activator agent
CN116615195A (zh) * 2020-09-17 2023-08-18 阿尔伯爱因斯坦医学院 使用bax激活剂的组合治疗
CN118715242A (zh) * 2021-10-05 2024-09-27 得克萨斯州大学系统董事会 包含b7-h3结合多肽的组合物和方法
CN114588269B (zh) * 2022-04-06 2023-06-27 宁波大学附属人民医院 Bcl-2抑制剂和HDAC抑制剂的组合物及其用途
WO2023238929A1 (ja) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 ピミテスピブを含有する医薬組成物
WO2024006292A2 (en) * 2022-06-27 2024-01-04 Foghorn Therapeutics Inc. Methods of treating cancer
CN115957328A (zh) * 2022-07-13 2023-04-14 杭州百可生物科技有限公司 一种用于治疗白血病的药物组合物以及白血病的治疗方法
CN115920062A (zh) * 2022-11-14 2023-04-07 北京清华长庚医院 联合用药物及其在预防或治疗肝癌中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060253A2 (en) 2009-11-13 2011-05-19 Myrexis, Inc. Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
KR101783676B1 (ko) * 2010-02-12 2017-10-10 니키 파머 액퀴지션 코포레이션 2 혈액암의 치료 방법
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
BR112013027448A2 (pt) * 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
CA3052594A1 (en) 2017-02-03 2018-08-09 AI Therapeutics, Inc. Methods for treating cancer using hsp90 inhibitors
CA3076915A1 (en) 2017-09-27 2019-04-04 AI Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors

Also Published As

Publication number Publication date
KR20190110128A (ko) 2019-09-27
CN110536702A (zh) 2019-12-03
IL268430A (en) 2019-09-26
JP2020505433A (ja) 2020-02-20
AU2018215336A1 (en) 2019-09-12
US20180221376A1 (en) 2018-08-09
MX2019009227A (es) 2020-02-12
RU2019127350A (ru) 2021-03-03
US20210030759A1 (en) 2021-02-04
WO2018144680A1 (en) 2018-08-09
TW201840337A (zh) 2018-11-16
CA3052594A1 (en) 2018-08-09
RU2019127350A3 (cg-RX-API-DMAC7.html) 2021-05-31
US10799508B2 (en) 2020-10-13
EP3576794A1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
US10799508B2 (en) Methods for treating cancer using HSP90 inhibitors
BR112020006009A2 (pt) métodos terapêuticos relacionados a inibidores de hsp90
US11266654B2 (en) Apilimod compositions and methods for using same
CN107249638B (zh) 阿匹莫德用于治疗肾癌
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
US20200222403A1 (en) Cerdulatinib for treating myeloma
NZ722491B2 (en) Apilimod compositions and methods for using same
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma
CN105228611A (zh) 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements